1. Home
  2. UBFO vs CHRS Comparison

UBFO vs CHRS Comparison

Compare UBFO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Security Bancshares

UBFO

United Security Bancshares

N/A

Current Price

$10.36

Market Cap

182.7M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.82

Market Cap

186.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UBFO
CHRS
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.7M
186.0M
IPO Year
2001
2014

Fundamental Metrics

Financial Performance
Metric
UBFO
CHRS
Price
$10.36
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
14.7K
1.7M
Earning Date
04-23-2026
06-01-2026
Dividend Yield
4.66%
N/A
EPS Growth
N/A
472.00
EPS
0.51
1.43
Revenue
$2,918,000.00
N/A
Revenue This Year
N/A
$88.67
Revenue Next Year
N/A
$28.64
P/E Ratio
$20.24
$1.36
Revenue Growth
N/A
N/A
52 Week Low
$7.32
$0.72
52 Week High
$11.52
$2.62

Technical Indicators

Market Signals
Indicator
UBFO
CHRS
Relative Strength Index (RSI) 38.44 52.43
Support Level $8.31 $1.55
Resistance Level $10.53 $1.89
Average True Range (ATR) 0.26 0.10
MACD -0.06 0.02
Stochastic Oscillator 16.35 59.30

Price Performance

Historical Comparison
UBFO
CHRS

About UBFO United Security Bancshares

United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: